About Nicole Luosey

This author has not yet filled in any details.
So far Nicole Luosey has created 5 blog entries.

Cadent Therapeutics Announces FDA Clearance of IND Application and Dosing of Subjects of CAD-9303 for Schizophrenia

By |2020-03-10T12:24:03+00:00March 10th, 2020|

CAMBRIDGE, Mass., March 10, 2020 – Cadent Therapeutics, a company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced that the U.S. Food and Drug Administration (FDA) has provided clearance to proceed for its Investigational New Drug (IND) application for its lead cognitive disorder asset, CAD-9303, a novel, first-in-class, positive allosteric modulator (PAM) of N-methyl-D-aspartate (NMDA) receptors for the treatment of the cognitive deficits and negative symptoms of schizophrenia. Dosing of patients is now underway in the Phase 1 clinical trial. “This IND clearance and initiation of dosing represents a critical milestone for Cadent as we progress CAD-9303 forward as the first drug candidate in our psychiatric disorders pipeline,” stated Jodie Morrison, Chief Executive Officer. “CAD-9303 serves as the first NMDA PAM to be developed to potentially transform the lives of patients with schizophrenia.”

Cadent Therapeutics to Present at the Cowen 40th Annual Health Care Conference

By |2020-02-26T13:03:00+00:00February 26th, 2020|

CAMBRIDGE, Mass., February 26, 2020 – Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced that Jodie Morrison, the Company’s Chief Executive Officer, will present at the Cowen 40th Annual Health Care Conference on Monday, March 2, 2020 at 4:00-4:25 pm ET at the Boston Marriott Copley Place.

Cadent Therapeutics to Present at the 9th Annual SVB Leerink Global Healthcare Conference

By |2020-02-19T21:06:47+00:00February 19th, 2020|

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced that Jodie Morrison, the Company’s Chief Executive Officer, will present at the 9th Annual SVB Leerink Global Healthcare Conference on Tuesday, February 25, 2020 at 1:45 pm ET at the Lotte New York Palace.

Cadent Therapeutics Announces Poster Presentation at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress

By |2020-02-06T21:10:17+00:00February 6th, 2020|

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced that the Company's Cadence-1 study will be highlighted in a poster presentation at the 3rd Pan American Parkinson’s Disease and Movement Disorders Congress from February 14-16, 2020 at the InterContinental Miami in Miami, Florida.

Cadent Therapeutics Announces FDA acceptance of IND Application for CAD-1883 for Spinocerebellar Ataxia (SCA)

By |2020-01-24T19:44:31+00:00January 23rd, 2020|

Cadent Therapeutics, a clinical stage biopharmaceutical company focused on the development of therapies to improve the lives of patients with movement, mood, and cognitive disorders, today announced the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial for CAD-1883...